News & Updates
Filter by Specialty:
Postoperative neutropaenia tied to early CRBSI in children with leukaemia
Paediatric patients with acute myeloid leukaemia and other leukaemias (AML/OLs), especially those with persistent neutropaenia during the first 30 postoperative days, are at increased risk of early catheter-related bloodstream infections (CRBSIs), according to a Singapore study.
Postoperative neutropaenia tied to early CRBSI in children with leukaemia
05 Jan 2023
TACE + apatinib: A potential new strategy for intermediate/advanced HCC?
In patients with intermediate or advanced hepatocellular carcinoma (HCC), combining transarterial chemoembolization (TACE) with apatinib led to improvement in progression-free survival (PFS), according to a recent study from China.
TACE + apatinib: A potential new strategy for intermediate/advanced HCC?
28 Dec 2022
Updated monarchE results show improved treatment effects of abemaciclib for breast cancer
In the preplanned overall survival (OS) interim analysis of the monarchE study, the combination of abemaciclib and endocrine therapy (ET) continued to provide benefit for individuals with HR+, HER2–, node-positive, high-risk early breast cancer even after completion of therapy.
Updated monarchE results show improved treatment effects of abemaciclib for breast cancer
28 Dec 2022
Relugolix effective, well tolerated in Asian men with advanced prostate cancer
In the subgroup analysis of the HERO trial, the first-in-class oral, highly selective, GnRH* antagonist relugolix was effective and well tolerated in Asian men with advanced prostate cancer.
Relugolix effective, well tolerated in Asian men with advanced prostate cancer
23 Dec 2022
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
